Literature DB >> 22439023

Severe, early onset hypertrophic cardiomyopathy in a family with LEOPARD syndrome.

Giuseppe Limongelli1, Giuseppe Pacileo, Maria Giovanna Russo, Anna Sarkozy, Maria Felicetti, Giovanni Di Salvo, Carmela Morelli, Paolo Calabrò, Dario Paladini, Bruno Marino, Bruno Dallapiccola, Raffaele Calabrò.   

Abstract

OBJECTIVE: Leopard syndrome is an acronym (multiple Lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) describing an autosomal dominant disease due to mutations in the raS-MapK pathway.
METHODS: Here, we describe a family (mother and daughter) with clinical and molecular diagnosis of Leopard syndrome 1 and HCM, and we report the prenatal diagnosis of HCM in a fetus at risk for Leopard syndrome.
RESULTS: An echocardiography was conducted showing a significant hypertrophy of both ventricles (left and right ventricular wall thickness 9mm and 3 mm). After a multidisciplinary counseling the couple opted for the termination of pregnancy
CONCLUSION: Further genotype-phenotype studies are warranted to fully elucidate the impact of the genotype on the natural history of patients with LS and LVH.

Entities:  

Keywords:  LEOPARD syndrome; hypertrophic cardiomyopathy; natural history; prenatal diagnosis

Year:  2008        PMID: 22439023      PMCID: PMC3279083     

Source DB:  PubMed          Journal:  J Prenat Med        ISSN: 1971-3282


  11 in total

Review 1.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

2.  Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study.

Authors:  Alan W Nugent; Piers E F Daubeney; Patty Chondros; John B Carlin; Steven D Colan; Michael Cheung; Andrew M Davis; C W Chow; Robert G Weintraub
Journal:  Circulation       Date:  2005-08-22       Impact factor: 29.690

3.  Is sudden cardiac death predictable in LEOPARD syndrome?

Authors:  Giuseppe Limongelli; Giuseppe Pacileo; Raffaele Calabrò
Journal:  Cardiol Young       Date:  2006-12       Impact factor: 1.093

4.  Cardiomyopathic lentiginosis/LEOPARD syndrome presenting as sudden cardiac arrest.

Authors:  A Woywodt; J Welzel; H Haase; A Duerholz; U Wiegand; J Potratz; A Sheikhzadeh
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

5.  Fetal cardiomyopathies: pathogenic mechanisms, hemodynamic findings, and clinical outcome.

Authors:  Simone R F F Pedra; Jeffrey F Smallhorn; Greg Ryan; David Chitayat; Glenn P Taylor; Rubina Khan; Mohamed Abdolell; Lisa K Hornberger
Journal:  Circulation       Date:  2002-07-30       Impact factor: 29.690

6.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

7.  Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome.

Authors:  Giuseppe Limongelli; Giuseppe Pacileo; Bruno Marino; Maria Cristina Digilio; Anna Sarkozy; Perry Elliott; Paolo Versacci; Paolo Calabro; Andrea De Zorzi; Giovanni Di Salvo; Petros Syrris; Michael Patton; William J McKenna; Bruno Dallapiccola; Raffaele Calabro
Journal:  Am J Cardiol       Date:  2007-06-27       Impact factor: 2.778

8.  Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome.

Authors:  Giuseppe Limongelli; Anna Sarkozy; Giuseppe Pacileo; Paolo Calabrò; Maria Cristina Digilio; Valeria Maddaloni; Giulia Gagliardi; Giovanni Di Salvo; Maria Iacomino; Bruno Marino; Bruno Dallapiccola; Raffaele Calabrò
Journal:  Am J Med Genet A       Date:  2008-03-01       Impact factor: 2.802

9.  Hypertrophic cardiomyopathy in infants: clinical features and natural history.

Authors:  B J Maron; A J Tajik; H D Ruttenberg; T P Graham; G F Atwood; B E Victorica; J T Lie; W C Roberts
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

10.  Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.

Authors:  Bhaswati Pandit; Anna Sarkozy; Len A Pennacchio; Claudio Carta; Kimihiko Oishi; Simone Martinelli; Edgar A Pogna; Wendy Schackwitz; Anna Ustaszewska; Andrew Landstrom; J Martijn Bos; Steve R Ommen; Giorgia Esposito; Francesca Lepri; Christian Faul; Peter Mundel; Juan P López Siguero; Romano Tenconi; Angelo Selicorni; Cesare Rossi; Laura Mazzanti; Isabella Torrente; Bruno Marino; Maria C Digilio; Giuseppe Zampino; Michael J Ackerman; Bruno Dallapiccola; Marco Tartaglia; Bruce D Gelb
Journal:  Nat Genet       Date:  2007-07-01       Impact factor: 38.330

View more
  4 in total

Review 1.  An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.

Authors:  Jae-Sung Yi; Sravan Perla; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-14       Impact factor: 3.727

2.  Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.

Authors:  Jae-Sung Yi; Sravan Perla; Yan Huang; Kana Mizuno; Frank J Giordano; Alexander A Vinks; Anton M Bennett
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-10       Impact factor: 3.947

Review 3.  Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies.

Authors:  Andreas Brodehl; Hans Ebbinghaus; Marcus-André Deutsch; Jan Gummert; Anna Gärtner; Sandra Ratnavadivel; Hendrik Milting
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

Review 4.  Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform-A Cardiac Perspective.

Authors:  Mohamed M Bekhite; P Christian Schulze
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.